Wednesday, September 16, 2015 3:52:29 PM
9/16/15, 7:40 AM
07:40 AM EDT, 09/16/2015 (MT Newswires) -- NovaBay Pharmaceuticals (NBY) a biopharmaceutical developer of non-antibiotic antimicrobial products for the eyes, Wednesday reported that its prescription daily eyelid and lash hygiene product Avenova will be marketed through ALLDocs Optometry Group, aka The Association of LensCrafters Leaseholding Doctors, the second-largest independent optometry group in the U.S.
NovaBay said the agreement with will bring Avenova to "hundreds of additional optometrists and thousands of additional patients."
NovaBay said Lenscrafters follows on previous distribution agreements with McKesson (MCK), Cardinal Health (CAH), AmerisourceBergen (ABC) and Vision Source, the latter the largest independent optometry network in the U.S. NovaBay said it also sells to the majority of the nation's 67,000 pharmacies and many retail chains.
Price: 0.42, Change: , Percent Change:
http://www.mtnewswires.com Copyright © 2015 MTNewswires. All rights reserved. MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.
Recent NBY News
- NovaBay Pharmaceuticals to Hold 2024 First Quarter Conference Call on May 9, 2024 • Business Wire • 05/03/2024 10:50:00 AM
- NovaBay Pharmaceuticals Announces New and Enhanced Direct-to-Consumer Marketing to Efficiently Engage Customers and Drive Avenova Sales • Business Wire • 04/22/2024 10:57:00 AM
- NovaBay Pharmaceuticals Receives a NYSE American Notice Regarding Stockholder Equity • Business Wire • 04/19/2024 10:00:00 PM
- NovaBay Pharmaceuticals Reports Preliminary Eyecare and Wound Care Revenue Increased 13% for the First Quarter of 2024 on Lower Sales and Marketing Expenses • Business Wire • 04/17/2024 10:59:00 AM
- NovaBay Pharmaceuticals Reports 2023 Fourth Quarter and Full Year Financial Results • Business Wire • 03/26/2024 08:05:00 PM
- NovaBay Pharmaceuticals to Hold 2023 Fourth Quarter and Full Year Conference Call on March 26, 2024 • Business Wire • 03/25/2024 10:38:00 PM
- NovaBay Pharmaceuticals Announces Agreement to Sell its DERMAdoctor Skincare Business Segment; Announces Preliminary Financial Results for Fourth Quarter and Year Ended December 31, 2023 • Business Wire • 03/14/2024 12:00:00 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 07:52:33 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/06/2024 04:52:28 PM
- NovaBay Pharmaceuticals Reports 64% Year-Over-Year Growth in Avenova Unit Subscription-Based Sales • Business Wire • 01/30/2024 02:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/10/2024 01:00:12 PM
- NovaBay Pharmaceuticals and Sonoma Pharmaceuticals Agree to Market Avenova-branded Products in the European Union Through Sonoma’s Extensive Distributor Network • Business Wire • 01/09/2024 02:15:00 PM
- Form D - Notice of Exempt Offering of Securities • Edgar (US Regulatory) • 01/04/2024 04:50:36 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/21/2023 12:58:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/11/2023 09:32:03 PM
- NovaBay Pharmaceuticals Partners with Woo University to Educate Eyecare Professionals on the Use of Amniotic Membranes • Business Wire • 12/06/2023 11:50:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:10:51 PM
- NovaBay Pharmaceuticals Reports Third Quarter 2023 Financial Results • Business Wire • 11/09/2023 09:05:00 PM
- NovaBay Pharmaceuticals to Hold Third Quarter 2023 Conference Call on November 9, 2023 • Business Wire • 11/02/2023 10:50:00 AM
- NovaBay Pharmaceuticals Expands Physician Dispensed Sales Channel with New Avenova Programs • Business Wire • 10/11/2023 12:00:00 PM
- NovaBay Pharmaceuticals to Present at the Dawson James Small Cap Growth Conference • Business Wire • 10/02/2023 10:50:00 AM
- Dawson James Securities Announces October Date for 8th Annual Small Cap Growth Conference • GlobeNewswire Inc. • 09/21/2023 01:35:00 PM
- NovaBay Pharmaceuticals Announces Commercial Launch of Avenova® Allograft • Business Wire • 09/14/2023 12:00:00 PM
- NovaBay Pharmaceuticals Announces Agreement with BioStem Technologies to Commercialize Amniotic Tissue Allograft as Avenova® Allograft • Business Wire • 09/11/2023 12:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/10/2023 08:47:15 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM